Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Accounts Payables (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Accounts Payables data on record, last reported at $2.3 million in Q4 2025.

  • For Q4 2025, Accounts Payables fell 46.25% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $2.3 million, down 46.25%, while the annual FY2025 figure was $2.3 million, 46.25% down from the prior year.
  • Accounts Payables reached $2.3 million in Q4 2025 per TRDA's latest filing, down from $3.2 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $6.5 million in Q1 2023 and bottomed at $752000.0 in Q3 2023.
  • Average Accounts Payables over 4 years is $2.9 million, with a median of $2.5 million recorded in 2023.
  • Peak YoY movement for Accounts Payables: tumbled 60.97% in 2024, then soared 145.05% in 2025.
  • A 4-year view of Accounts Payables shows it stood at $6.0 million in 2022, then crashed by 45.29% to $3.3 million in 2023, then grew by 29.97% to $4.3 million in 2024, then crashed by 46.25% to $2.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $2.3 million in Q4 2025, $3.2 million in Q3 2025, and $1.9 million in Q2 2025.